» Articles » PMID: 16404431

Changes in the Serum Proteome Associated with the Development of Hepatocellular Carcinoma in Hepatitis C-related Cirrhosis

Overview
Journal Br J Cancer
Specialty Oncology
Date 2006 Jan 13
PMID 16404431
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Early diagnosis of hepatocellular carcinoma (HCC) is the key to the delivery of effective therapies. The conventional serological diagnostic test, estimation of serum alpha-fetoprotein (AFP) lacks both sensitivity and specificity as a screening tool and improved tests are needed to complement ultrasound scanning, the major modality for surveillance of groups at high risk of HCC. We have analysed the serum proteome of 182 patients with hepatitis C-induced liver cirrhosis (77 with HCC) by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI). The patients were split into a training set (84 non-HCC, 60 HCC) and a 'blind' test set (21 non-HCC, 17 HCC). Neural networks developed on the training set were able to classify the blind test set with 94% sensitivity (95% CI 73-99%) and 86% specificity (95% CI 65-95%). Two of the SELDI peaks (23/23.5 kDa) were elevated by an average of 50% in the serum of HCC patients (P<0.001) and were identified as kappa and lambda immunoglobulin light chains. This approach may permit identification of several individual proteins, which, in combination, may offer a novel way to diagnose HCC.

Citing Articles

The combination of serum oligosaccharide chain (G-test), alpha-fetoprotein, and aspartate aminotransferase to alanine aminotransferase ratio provides the optimal diagnostic value for early detection of hepatocellular carcinoma.

Zhu W, Shi P, Liang A, Zhu Y, Fu J, Yuan S BMC Cancer. 2022; 22(1):1061.

PMID: 36241994 PMC: 9563102. DOI: 10.1186/s12885-022-10139-9.


Establishment and characterization of a highly immunogenic human renal carcinoma cell line.

Prattichizzo C, Gigante M, Pontrelli P, Stella A, Rocchetti M, Gigante M Int J Oncol. 2016; 49(2):457-70.

PMID: 27278998 PMC: 4922831. DOI: 10.3892/ijo.2016.3544.


Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma.

Teng M, Pirrie S, Ward D, Assi L, Hughes R, Stocken D Br J Cancer. 2014; 110(9):2277-82.

PMID: 24603305 PMC: 4007223. DOI: 10.1038/bjc.2014.121.


Predicting early intrahepatic recurrence of hepatocellular carcinoma after microwave ablation using SELDI-TOF proteomic signature.

Cao X, Li H, Yu X, Liang P, Dong B, Fan J PLoS One. 2013; 8(12):e82448.

PMID: 24349287 PMC: 3862627. DOI: 10.1371/journal.pone.0082448.


Identification of serum CCL15 in hepatocellular carcinoma.

Li Y, Wu J, Zhang W, Zhang N, Guo H Br J Cancer. 2013; 108(1):99-106.

PMID: 23321514 PMC: 3553511. DOI: 10.1038/bjc.2012.494.


References
1.
Khan J, Wei J, Ringner M, Saal L, Ladanyi M, Westermann F . Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med. 2001; 7(6):673-9. PMC: 1282521. DOI: 10.1038/89044. View

2.
Baggerly K, Morris J, Coombes K . Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics. 2004; 20(5):777-85. DOI: 10.1093/bioinformatics/btg484. View

3.
Adam B, Qu Y, Davis J, Ward M, Clements M, Cazares L . Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002; 62(13):3609-14. View

4.
Johnson P . The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001; 5(1):145-59. DOI: 10.1016/s1089-3261(05)70158-6. View

5.
Parkin D, Bray F, Ferlay J, Pisani P . Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94(2):153-6. DOI: 10.1002/ijc.1440. View